Objective: To evaluate the long-term oncological outcome of radical prostatectomy for patients with high-risk prostate cancer. Methods: Among 378 patients with prostate cancer who underwent radical prostatectomy at our hospital, 189 had high-risk prostate cancer defined as presenting with at least one of the following high-risk factors: prostate-specific antigen .20 ng/ml, clinical T3 and biopsy Gleason score 8. Results: The median follow-up was 8.1 years. Of all patients, 106 and 61 had one and two high-risk factors, respectively, and the remaining 22 had all three high-risk factors. Pathological examination of the prostatectomy specimens revealed organ-confined disease, specimen-confined disease and lymph node metastasis in 80 (42%), 102 (54%) and 22 (12%), respectively. The 10-year prostate-specific antigen failure-free and local progressionfree survival rates were 48.5 and 87.6%, respectively. The 10-year cancer-specific and overall survival rates were 94.1 and 88.7%, respectively. The 10-year prostate-specific antigen failure-free survivals of patients with one, two and all three high-risk factors were 58.5, 39.9 and 22.7%, respectively (P ¼ 0.0001). Of the 106 patients with one high-risk factor only, the high Gleason score group had the best 10-year prostate-specific antigen failure-free survival (69.1%); in particular, that of patients without Gleason grade 5 was 100% (P ¼ 0.032). Conclusions: Approximately half of patients with high-risk prostate cancer can be cured by radical prostatectomy without any adjuvant treatment. Radical prostatectomy for high-risk prostate cancer provides good long-term local cancer control and cancer-specific survival. In particular, radical prostatectomy for patients with only one high-risk factor can be considered a valuable therapeutic option as the first treatment.
INTRODUCTION
The widespread use of prostate-specific antigen (PSA) screening and more extensive biopsy strategy have led to an increase in the proportion of men who have been diagnosed with low-and intermediate-risk localized prostate cancer (PCA). However, 15% of all PCA patients continue to present with high-risk PCA with aggressive tumor biology (1) , which involves the possibility of cancer-related death. Although radical prostatectomy (RP) and external beam radiation therapy (EBRT) with or without high-dose rate brachytherapy are currently the main treatment strategies for high-risk PCA patients, RP used to be a second-choice treatment option for urologists as it was considered to be unsuitable for high-risk PCA. Recently, however, RP has been aggressively performed on patients with high-risk PCA and several investigators have reported excellent oncological outcomes (2,3). Ploussard et al. (4) reported that the 3-year biochemical recurrence-free survival rate of 110 patients with high-risk PCA who underwent laparoscopic RP was 69.8%. Masson-Lecome et al. (5) also reported that the 5-year PSA recurrence-free survival rate of 138 patients with high-risk PCA who underwent RP was 40%. They therefore concluded that RP was an optimal treatment for patients with high-risk PCA. However, because the follow-up period in most of these reports was relatively short and the definition of highrisk PCA varied, it is difficult to directly compare the oncological outcomes of these reports (4, 5) .
Furthermore, as most risk classifications of PCA consist solely of the pretreatment PSA level, biopsy Gleason score (bGS) and the clinical stage are simple and useful in clinical practice (6 -8) , however, their disadvantage is that the range of each risk group is wide. As such, in the treatment strategy of patients with high-risk PCA, a more detailed subclassification may be needed.
Recently, Walz et al. (9) examined that the oncological outcome of RP for 887 men with high-risk PCA and reported that 10-year biochemical recurrence-free survival rates of the men with one and two high-risk factors were 37.2 and 17.9%, respectively. They concluded that men with high-risk PCA did not have a uniformly poor prognosis after RP. However, the median follow-up of this study was only 2.4 years.
To date, to the best of our knowledge, there has only been one report by Lodde et al. (10) that relates to the subclassification of men with high-risk PCA who underwent RP for long-term follow-up. Thus, we investigated the long-term oncological outcome of RP for men with high-risk PCA and examined a more detailed subclassification of the high-risk PCA group.
PATIENTS AND METHODS

PATIENT POPULATION
Between July 1994 and December 2003, a total of 378 Japanese patients with clinically localized or locally advanced PCA underwent RP and bilateral limited or standard pelvic lymphadenectomy (obturator region) at the Cancer Institute Hospital in Tokyo, Japan. Of the 378 patients, 189 (50%) had high-risk PCA (PSA .20 ng/ml and/or clinical T3 and/or bGS of 8). Ninety-nine (52%) patients received neoadjuvant androgen deprivation therapy (NADT) before surgery.
STAGING AND FOLLOW-UP
Clinical staging was determined according to the 1997 tumor-node-metastasis (TNM) classification. Digital rectal examination, abdominopelvic computed tomography and bone scan were performed in all patients. Since 1999, pelvic magnetic resonance imaging (MRI) has also been carried out to determine the T stage. All MRI findings were determined by a single radiologist (A.K). PSA measurements after RP were performed as reported previously (11 -13) .
SURGICAL TECHNIQUE AND PATHOLOGIC EXAMINATION
All RP were carried out as reported previously (11 -13) . Seven of the 189 patients (4%) underwent a unilateral nervesparing procedure.
RP specimens were processed as reported previously (11 -13) . Histopathological grading of the RP specimen was performed according to the GS system by a single pathologist (Y.I.).
HORMONAL TREATMENT
Combined androgen blockade (luteinizing hormone-releasing hormone agonist and a non-steroidal antiandrogen agent) was used as NADT in the majority of the current study patients. Based on Gleave's et al. report (14) , the period of NADT was 8 -10 months as a rule. However, because of the retrospective nature of the study, the use and the period of NADT were decided at the discretion of the attending physician.
After RP, 176 patients (93%) were prospectively observed without any adjuvant treatment until PSA failure was confirmed. Exceptions to this protocol were 11 patients who received salvage ADT for persistently elevated PSA following RP and/or adverse pathological findings (lymph node metastasis and seminal vesicle involvement) and 2 who concurrently underwent surgical castration with RP.
ONCOLOGICAL OUTCOMES
Oncological outcomes in terms of PSA failure-free, local progression-free, cancer-specific and overall survival rates were evaluated. PSA failure was defined as a PSA level .0.2 ng/ml. In the 13 patients who received salvage ADT, including concurrent surgical castration with RP, the day of the surgery was considered the day of PSA failure. Local progression was defined as an intrapelvic recurrent mass. The cause of death was identified from death certificates or physician correspondence.
STATISTICAL ANALYSIS
PSA failure-free, local progression-free, cancer-specific and overall survival curves were generated with the KaplanMeier method. A log-rank test was performed to test associations between the variables and PSA failure-free survival. Cox regression analysis was used to generate the hazard ratio (HR) according to the number of high-risk factors for PSA failure.
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All P-values were two-sided. A P-value of ,0.05 was considered statistically significant. Statistical analyses were performed with JMP version 5.1.1 (SAS Institute Inc., Cary, NC, USA).
RESULTS
PATIENT CHARACTERISTICS AND PATHOLOGICAL FINDINGS AFTER RP
Patient characteristics are presented in Table 1 . The median pretreatment PSA level was 24.0 (ng/ml). Approximately 50% of all patients had high-grade cancer (GS of 8) on biopsy. Approximately 50% of all patients received NADT for a median of 8 months. Clinical T-stage was clinical T1c-2, T3a and T3b in 104 (55%), 63 (33%) and 22 (12%), respectively. The patients who received NADT before RP (NADT group) had higher PSA (P , 0.001), higher clinical T-stage (P , 0.001) and a greater number of high-risk factors (P , 0.001) than those who did not receive NADT before RP (Non-NADT group).
Of all patients, 106 (56%) had one high-risk factor, PSA .20 ng/ml (22%) or clinical stage T3 (10%) or bGS of 8 (24%); 61 (32%) patients had two high-risk factors and the remaining 22 had all three high-risk factors.
The pathological outcome of the 189 patients is summarized in Table 2 . Although 80 (42%) and 102 (54%) had organ-confined disease (OCD) and specimen-confined disease (SCD), respectively, 63 (33%) and 22 (12%) had positive surgical margins (PSMs) and lymph node metastasis, respectively. Although the PSM rate of the NADT group was lower than that of the non-NADT group (P ¼ 0.03), the percentages of OCD and SCD between the NADT and non-NADT groups were not statistically significant (P ¼ 0.23 and 0.45).
ONCOLOGICAL OUTCOMES
During a median follow-up time of 8.1 years (range: 0.3 -16.8), PSA failure was observed in 94 patients (50%), including 11 patients who received salvage ADT for persistently elevated PSA following RP and/or adverse pathological findings and two who concurrently underwent surgical castration with RP. Local progression was also observed in 20 patients (10.6%). Of the 20 patients with local progression, 11 had anastomotic recurrence and 9 had pelvic lymph node metastasis. As shown in Fig. 1a , the 5-and 10-year PSA failure-free survival rates were 53.4 and 48.5%, respectively. The 5-and 10-year local progression-free survival rates were 91.5 and 87.6%, respectively (Fig. 1b) .
During the follow-up period, there were 18 deaths (10%), including 9 PCA-related deaths (50%).The cancer-specific survival rates (CSS) were 97.7 and 94.1%, at 5 and 10 years, respectively (Fig. 1c) . The overall survival rates were 93.9 and 88.7% at 5 and 10 years, respectively (Fig. 1d) . PSA failure-free survival rates between the NADT and non-NADT groups were not significantly different, regardless of the number of high-risk factors (Table 3 ). All other oncological outcomes were also not significantly different between the two groups (data not shown).
SUBSTRATIFICATION OF HIGH-RISK PCA
The 10-year PSA failure-free survival rates of PCA patients with one, two and all three high-risk factors were 58.5, 39.9 and 22.7%, respectively (P ¼ 0.0001, Fig. 2a and Table 3 ). (Table 3) . Of the 106 patients with only one high-risk factor, the 10-year PSA failure-free survival rates of patients with high GS, clinical high T-stage and high PSA only were 69.1, 56.1 and 47.8%, respectively (P ¼ 0.0058, Fig. 2b) . Further, the 10-year PSA failure-free survival rates of high GS groups with and without a Gleason grade (GG) 5 were 57.4 and 100%, respectively; thus, there was a statistical significance between the groups (P ¼ 0.032, Fig. 2c ).
DISCUSSION
Our retrospective study revealed two important findings. First, RP for high-risk PCA provides good long-term oncological outcome and local cancer control. To date, there have been only three reports (10, 15) , including the present study, on the long-term oncological outcome of RP for high-risk PCA. Boorjar et al. reported that the 10-year cancer-specific and overall survival rates of high-risk PCA treated with RP were 92 and 77%, respectively, at a median follow-up of 10.2 years. Therefore, they concluded that RP and EBRT plus ADT for high-risk PCA provided similar long-term cancer control (15). Lodde et al. (10) also reported that the PSA-FFS, prostate-specific antigen failure-free survival; NADT, neoadjuvant androgen deprivation therapy; HR, hazard ratio; CI, confidence interval. 10-year PCA-specific mortality (PCSM) of the 290 men with high-risk PCA was only 10.3% at a median follow-up of 8.18 years. It may be difficult to compare these reports directly because many patients in the cohort of Boorjar et al. (15) had received any adjuvant treatments after RP. Moreover, the definition of high-risk PCA also differed between these two reports (10, 15) . Considering these three reports, including our study, however, the 10-year CSS rate of high-risk PCA treated with RP is 90%. Some investigators have demonstrated the various advantages of RP for high-risk PCA (9, 15, 16) . They insist that RP for high-risk PCA is acceptable local cancer control and that it enables the gathering of specific anatomopathological information that is likely to help accurately predict the outcome and thus pinpoint patients who are likely to benefit from adjuvant treatments (16, 17) . Yossepowitch et al. (18) investigated the pathological characteristics and the outcome of patients with high-risk factors based on eight previously described definitions. They concluded that because it was difficult to correctly predict the outcome of patients who were not good candidates for RP using some definitions of high-risk PCA, urologists should not uniformly disqualify patients from undergoing curative surgery.
Second, the oncological outcome of RP for patients with one, two and all three high-risk factors was various, namely, patients with high-risk PCA did not have a uniformly poor prognosis after RP. In our study, the 10-year PSA failure-free survival rate of high-risk PCA patients with one, two and all three high-risk factors was 58.5, 39.9 and 22.7%, respectively, (P ¼ 0.0001) and PCA patients with two or all three highrisk factors had HRs of 1.89 (95% CI: 1.20 -2.98, P ¼ 0.006) and 2.99 (95% CI: 1.64-5.21, P ¼ 0.0006) when compared with PCA patients with only one high-risk factor. This finding can be interpreted as indicating that although patients with only one high-risk factor who underwent RP may be cured by RP without any adjuvant treatments, it is difficult for patients with all three high-risk factors to be cured by RP monotherapy and, therefore, RP for them may be considered as a first step of multimodal treatment with adjuvant radiation therapy and/or ADT. Lodde et al. (10) reported that in the 1109 RP series, the 10-year biochemical recurrence-free survival and PCSM rates of PCA patients with no, one and two high-risk factors were 75.5, 49.4 and 35.2%, and 1.4, 7.9 and 16.1%, respectively. Therefore, they concluded that a more detailed substratification in the high-risk PCA group is needed to predict the correct oncological outcome of patients in the group. Spahn et al. investigated the oncological outcome of 712 patients with PSA .20 ng/ml who underwent RP. They reported that the rates of patients with favorable pathology for patients with PSA .20 ng/ml, PSA .20 ng/ml and clinical T3 stage, PSA .20 ng/ml and bGS of 8 and all three risk factors were 27, 11.1, 1.9 and 0%, respectively (19) They concluded that PCA patients with PSA .20 ng/ml have varying risk levels of disease progression and PCSM. Considering additional risk factors further stratifies this group into subgroups that can guide the clinician in preoperative patient counseling.
In our study, of the 105 patients with only one high-risk factor, the high GS group had the best 10-year PSA failurefree survival rate (74.6%). In particular, that of patients without GG 5 was 100% (P ¼ 0.032). Therefore, we believe that patients with high GS alone, especially those without GG 5 are the most suitable RP candidates in the high-risk PCA group. Nanda et al. (20) performed EBRT or RP for 312 PCA patients with clinical T1c-3N0M0 and bGS of 7 with tertiary GG 5 or bGS 8 -10. They reported that the PSA failure rate of patients with bGS of 8 was significantly lower than that of patients with bGS of 9, and that of patients with bGS 7 with tertiary GG 5 was almost the same as of patients with bGS of 9 -10. They concluded that patients with high GS should be subclassified into bGS of 8, 9 -10 and 7 with tertiary GG 5. Wambi et al. (21) also emphasized the oncological differences between bGS of 8 and 9 tumors. They analyzed the oncological outcome of 368 patients with bGS of 8 -9 who underwent robotic RP and reported that their PSM rates were 40 and 64%, respectively. Furthermore, the 5-year biochemical recurrence-free survival rates of patients with bGS of 8 and 9 were 47 and 21%, respectively (P , 0.001). We agree with the conclusions of these two investigative teams regarding the significance of the existence of GG 5 in relation to the prognosis of patients with high-risk PCA.
Our study has several limitations. First, the patient number in our cohort was relatively small and some of the final pathological findings were unclear because approximately half of the patients received NADT before RP. Second, we could not analyze the subclassification of high-risk PCA with regard to mortality related to PCA and all events because the number of events was too small.
In conclusion, RP can be considered as a valuable therapeutic option for patients with one high-risk factor, especially for those without GG 5 in the high GS group.
In contrast, RP monotherapy has apparent limitations for patients with all three high-risk factors. In these patients, RP can be performed as the initial treatment strategy, but should be considered as a part of multimodal treatment. Thus, because patients with high-risk PCA do not have a uniform prognosis after RP, a more detailed subclassification of the high-risk patients according to the number of high-risk factors can offer further prognostic information.
